Blau Farmacêutica

What Blau Farmacêutica does

Blau Farmacêutica S/A is a Brazilian pharmaceutical company founded in 1987 by Marcelo Rodolfo Hahn, headquartered in Cotia, São Paulo, and publicly listed on B3 (ticker BLAU3) since April 2021 on the Novo Mercado governance segment. The company pioneered biotechnological pharmaceutical production in Brazil in 1998 and operates three business units: Onco-hemato & Especialidades (institutional/hospital channel), Farma/OTC (retail pharmacy), and Blaū Aesthetics (professional aesthetics). Its portfolio spans high-complexity hospital medicines (antibiotics, antivirals, anticoagulants, anesthetics), oncology products (chemotherapeutics, monoclonal antibodies, biosimilars), biological and biotechnological medicines, Active Pharmaceutical Ingredients, and consumer health products including the Preserv condom line.

The company's technology platform centers on the Inventta R&D center (160+ researchers including ~30 PhDs) and vertically integrated manufacturing: five specialized pharmaceutical production plants in Brazil (Cotia, São Paulo, Anápolis, Taboão da Serra, Caucaia) plus a dedicated R$200 million, 3,000+ m² biotechnological IFA plant also in Cotia. Blau develops recombinant human proteins through genetically modified prokaryotic and eukaryotic cell lines, with upstream bioreactor and downstream preparative chromatography capabilities, targeting immunology, hematology, oncology, nephrology, infectology, and anesthesiology therapeutic areas. Development cycles for biosimilars run 7-10 years. GMP certifications are held from ANVISA, INVIMA (Colombia), and DIGEMID (Peru).

Blau generates revenue through direct sales to institutional/hospital channels via specialized distributors, retail pharmacy distribution for OTC products, dedicated sales to aesthetic healthcare professionals, and plasma collection operations through Hemarus centers in Florida. The company has expanded across seven Latin American countries through wholly-owned subsidiaries (Argentina, Uruguay, Colombia, Peru, Chile) and maintains a European equity interest in Prothya, a plasma fractionator. Founder Marcelo Rodolfo Hahn controls 82.50% of shares directly, with 16.55% in free float.

Name

Blau Farmacêutica

Legal name

Blau Farmacêutica S/A

Website

https://blau.com

Company type

Public

Founded year

1987

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Blau Farmacêutica is a publicly listed Brazilian pharmaceutical manufacturer pioneering biotechnology since 1998, producing high-complexity hospital medicines, oncology products, biosimilars, and APIs across three business units serving institutional, retail, and aesthetics markets in 7+ Latin American countries.

Ownership category

akta.pro rank

Product category

Biopharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Oncology Biosimilars (HLAAAHAG)

akta.pro secondary industries

Monoclonal Antibody (mAb) Biosimilars (HLAIAFAA), Biologics & Biosimilars Distributors (HLAIAJAH), Bio-based Pharmaceuticals, Nutraceuticals & Specialty Bioactives (EUAAAIAK)

Keywords

• Biopharmaceutical manufacturing
• Biosimilar medicines
• Hospital pharmaceuticals
• Active pharmaceutical ingredients
• Injectable aesthetics

Headquarters

HQ city

Cotia

HQ country

Brazil

HQ region

Latin America

Offices12 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Infrastructure, Technology or R&D, Operations, Personnel, Marketing or Sales, Supply Chain

Revenue model

1. Pharmaceutical Sales - Institutional/Hospital: Sales of high-complexity hospital medicines including antibiotics, antivirals, anticoagulants, hemoderivatives, muscle relaxants, analgesics, anesthetics for hospital care from emergency room to ICU and surgical centers. Includes oncology support medications such as antiemetics, white blood cell stimulants, and mucositis protectors.
2. Biotechnology/Biossimilar Products: Sales of biosimilar and biological products for immunology, hematology, oncology, nephrology applications. Includes recombinant human proteins produced through genetically modified cell lines.
3. Retail/OTC Pharmaceuticals: Sales of prescription and over-the-counter medicines including products for chronic diseases such as rheumatoid arthritis and anemia, gynecology, anticoagulants, gastroenterology, infectology, gels, and male condoms (Preserv line) sold at retail pharmacies.
4. Aesthetics Products: Sales of minimally invasive aesthetic treatment products under Blaū Aesthetics brand, targeting healthcare professionals specializing in aesthetic procedures.
5. Plasma Collection Services: Plasma collection through Hemarus centers in the United States (Lauderhill, Florida) supporting raw material supply for biopharmaceutical production.
6. Licensing and M&A Services: The company actively seeks partnerships, strategic alliances, and new business opportunities including acquisitions, joint ventures, and licensing of new products. Also evaluates international partners to license and commercialize their products in other countries.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels8 records

Core offering

Blau Farmacêutica is a vertically integrated Brazilian biopharmaceutical company that develops, manufactures and distributes high-complexity medicines across three business units: Onco-hemato & Especialidades (oncology, biosimilars, hospital medicines), Farma/OTC (prescription and consumer health products at retail pharmacies), and Blaū Aesthetics (injectable aesthetic treatments). The company produces biosimilars, biologicals, synthetic medicines and Active Pharmaceutical Ingredients (APIs), with proprietary biotechnology capabilities for recombinant proteins and monoclonal antibodies developed through its Inventta R&D center.

Product overview

Blau Farmacêutica operates as a pharmaceutical company with three main business units—Onco-hemato e Especialidades, Farma/OTC, and Blaū Aesthetics—offering a unified portfolio of high-complexity medications. The portfolio includes oncology products (chemotherapeutics, biosimilars, monoclonal antibodies), biological products, hospital medications (antibiotics, anesthetics, anticoagulants), active pharmaceutical ingredients, and consumer health products. The company integrates its Inventta R&D center for drug development and operates a dedicated biotechnology platform for producing recombinant proteins and biosimilars. With five pharmaceutical plants and one API plant in Brazil, plus international operations across Latin America and the US, the company covers therapeutic areas including immunology, hematology, oncology, nephrology, infectology, and anesthesiology.

Differentiator

Problem solved

Functional benefit

Brands

• Blaū Aesthetics: Aesthetic products division offering innovative solutions for minimally invasive aesthetic procedures, including injectable treatments for aesthetic practitioners.
• Inventta

Products and services

• Oncológicos (Oncology Products)
• Biológicos (Biological Products)
• Biofármacos / Ativos Farmacêuticos (Bio Drugs / Active Pharmaceutical Ingredients)
• Hospitalares (Hospital Products)
• Antibióticos (Antibiotics)
• Anestésicos (Anesthetics)
• Antirreumático (Antirheumatic)
• Estimulador Uterino (Uterine Stimulant)
• Antivirais e Antirretrovirais (Antivirals and Antiretrovirals)
• Inibidores de Bomba Ácida (Acid Pump Inhibitors)
• Hemoderivados (Hemoderivatives)
• Antitrombóticos (Antithrombotics)
• Trombolíticos (Thrombolytics)
• Linha de Produtos Femininos (Women's Health Products)
• Blaū Aesthetics (Aesthetic Products)
• Farma/OTC Products
• Preserv (Condoms)

Quantifiable outcome

• First company in Brazil to produce biotechnological products (1998)
• +4 more outcomes

Named customers1 record

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Six partnerships are on record, tiered core and minor.

• ProthyacoreStrategic or Co-development Partner · 1 January 2025Blau invested 50 million Euros in Prothya, acquiring an equity interest in the European plasma fractionation company. Prothya has its own drugs marketed globally, expanding Blau's presence in Europe and strengthening its plasma-derived product capabilities.
• Laboratório Químico Farmacêutico BergamocoreOthers · 1 January 2021Blau completed acquisition of Bergamo for US$33.2 million. CADE (Brazilian antitrust authority) approved the acquisition. Bergamo specializes in oncolytics, injectables and lyophilized products, strengthening Blau's hospital product portfolio.
• Green Cross CorporationcoreStrategic or Co-development PartnerLong-term contract agreement with Korean pharmaceutical company Green Cross Corporation for strategic collaboration in the pharmaceutical sector.
• HugelminorGTM or Marketing PartnerCollaborative participation in aesthetic medicine events with Hugel, including the Hugel Expert Leaders Forum and other industry conferences.
• Cepro (Centro Profissionalizante Rio Branco)minorImplementation/ SI/ Consulting PartnerPartnership with Cepro for the Young Apprentice program where 30% of time is theoretical training at Cepro facilities while 70% is practical work at Blau.
• HemaruscoreChannel Partner/ Reseller/ DistributorPlasma collection operations in the United States through Hemarus centers, collecting plasma for raw material supply supporting biopharmaceutical production.

Scale indicators13 records

Recent moves9 records

Expansion highlights6 records

Broad incumbents

• Amgen: Global biotechnology leader in biologics, biosimilars, and oncology. Relevant as a benchmark for the biosimilar/biologics technology and pipeline Blau is pursuing, while also representing the global competitive landscape Blau's biosimilar products ultimately compete against.
• Aspen Pharmacare: South African specialty pharma with strong emerging-market presence across Latin America, Africa, and Asia. Comparable in targeting emerging markets with hospital specialty and biosimilar-like products, but operates at much larger global scale.

Direct peers

• Cristália: Brazilian pharmaceutical company specializing in hospital medicines, injectables, anesthetics, and biosimilars. Direct overlap with Blau's Onco-hemato & Especialidades and hospital product lines.
• Biolab Farmacêutica: Brazilian specialty pharmaceutical company focused on prescription brands in cardiology, gynecology, dermatology, and central nervous system. Comparable mid-sized Brazilian specialty pharma model with similar therapeutic breadth to Blau's Farma unit.
• Eurofarma Laboratórios: Brazil's largest multinational pharmaceutical company, with comparable operations in prescription generics, hospital specialty pharmaceuticals, biotechnology, and exports across Latin America. Directly competes with Blau in Brazilian hospital injectables and specialty medicines.
• Aché Laboratórios: Brazilian pharma company with prescription, OTC, and hospital specialty portfolios. Direct competitor to Blau in Brazilian retail pharmacy and specialty therapeutic categories.
• União Química: Brazilian pharmaceutical manufacturer focused on hospital injectables, oncology, and specialty products. Closely comparable to Blau's hospital and oncology segments with similar institutional-channel go-to-market.
• EMS (Grupo NC): Largest Brazilian pharmaceutical manufacturer by revenue, with broad portfolios in generics, branded prescription, OTC, and hospital specialties. Competes with Blau's Farma/OTC and hospital units across Brazil.
• Laboratório Teuto: Large Brazilian generics and hospital manufacturer, with significant injectable and specialty portfolios. Comparable in manufacturing footprint, channel mix, and Brazilian institutional customer base.

Emerging players

• Biocon: Indian biopharmaceutical company and a global biosimilars leader (insulin, mAbs, oncology biologics). Relevant peer on biosimilar development capabilities and emerging-market positioning, though operates at larger scale and global footprint than Blau.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/channel/UCR3EHDD_Cfc7I9EaduCUFog
• Facebookfacebook.com/blaufarmaceutica
• LinkedInlinkedin.com/company/blaufarmaceutica
• Instagraminstagram.com/blaufarmaceutica

Compliance6 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles16 records

Subsidiaries8 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Blau Farmacêutica